Corbus Pharmaceuticals Holdings Inc.

Rank 36
About
Corbus Pharmaceuticals is a biopharmaceutical company in its third stage of preclinical trials. Their novel therapeutic treatments are aimed at inflammatory and fibrotic conditions. The primary mechanism for these treatments is the endocannabinoid system and the agitation of CB2 receptors. The company operates out of Norwood, Massachusetts.
$3.3799
USD
10.00%
Market cap
$218,515,919
Total volume
$137,533,973
Shares outstanding
64,651,593
Rank 36
About
Corbus Pharmaceuticals is a biopharmaceutical company in its third stage of preclinical trials. Their novel therapeutic treatments are aimed at inflammatory and fibrotic conditions. The primary mechanism for these treatments is the endocannabinoid system and the agitation of CB2 receptors. The company operates out of Norwood, Massachusetts.
Markets
Exchange | Symbol | Volume (24h) | Volume (%) | Price |
---|---|---|---|---|
|
CRBP |
$137,533,973
|
100% |
$3.3799
|
Chart